CollPlant Holdings Ltd. (TASE: CLPT) has recruited the first two patients for the Phase I clinical trial of its VergenixWD Wound Dressing matrix, made of pure recombinant human collagen. It is a pure human collagen scaffold that provides a moist wound healing environment.
The patients suffer from diabetic ulcers on their feet. The trial will take several months to a year, to test the safety of the matrix.
VergenixWD is a sterile biodegradable sheet supplied for the treatment of acute and chronic wounds. The sheets absorb the secretions from the wound to create a perfect moist micro-environment that effectively balances wound bed fluids. Human endothelial cells, fibroblasts and keratinocytes easily migrate through the human-collagen porous micro-structure to proliferate into new tissue.
While other collagen-based wound dressing are on the market, they are derived from animal collagen; VergenixWD is the first human-collagen based product.
CollPlant CEO Yehiel Tal said, "VergenixWD is the first CollPlant product to begin a clinical trial. It is the pioneer that will pave the way to a varied pipeline of company products. The data obtained from the trial will help in the regulatory process to obtain marketing approval for this and other company products that are based on human recombinant collagen."
CollPlant's share price was unchanged at NIS 0.59 by midday today, giving a market cap of NIS 71 million.
Published by Globes [online], Israel business news - www.globes-online.com - on January 4, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012